Recommended Topic Related To:

Temodar

"Dec. 22, 2010 -- Scientists say they've discovered a genetic defect that may contribute to the development of as many as one in four cases of glioblastoma, the most common and aggressive type of brain tumor.

The defect, a deletion in a "...

Temodar

Temodar Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Temodar (temozolomide) is used together with radiation therapy to treat certain types of brain tumor in adults. It is sometimes given after other cancer medications have been tried without successful treatment of the tumor. It is a chemotherapy drug. Common side effects include nausea, vomiting, loss of appetite, constipation, tiredness, weakness, and headache. Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

Dose of Temodar is individualized for each patient depending on the condition being treated. Temodar may interact with carbamazepine, divalproex sodium, phenytoin, valproic acid, steroids, or sulfa drugs. Tell your doctor all medications you are taking. Temodar is not recommended for use during pregnancy. It may harm a fetus. It is not known if this drug passes into breast milk. Due to the potential risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.

Our Temodar (temozolomide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Temodar in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • seizure (convulsions);
  • numbness or tingling on one side of your body;
  • signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, unusual weakness;
  • dry cough, feeling short of breath, weight loss, night sweats;
  • pain or burning when you urinate;
  • white patches or sores inside your mouth or on your lips; or
  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • hair loss;
  • tired feeling;
  • diarrhea, constipation;
  • mild skin rash;
  • dizziness, blurred vision;
  • sleep problems (insomnia); or
  • unusual or unpleasant taste in your mouth.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Temodar (Temozolomide) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Temodar Overview - Patient Information: Side Effects

SIDE EFFECTS: Nausea, vomiting, loss of appetite, constipation, tiredness, weakness, and headache may occur. Nausea and vomiting can be quite severe. Drug therapy may be necessary to prevent or relieve nausea and vomiting. Not eating before your treatment may help relieve vomiting. Changes in diet and lifestyle, such as eating several small meals or limiting activity, may help lessen some of these effects. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: mouth sores, swelling of the ankles/feet, easy bleeding or bruising, shortness of breath.

This medication can lower the body's ability to fight an infection. Notify your doctor promptly if you develop any signs of an infection such as: fever, chills, persistent sore throat, cough, burning/painful/frequent urination.

Although temozolomide is used to treat cancer, very rarely in some patients it may increase the risk of developing another form of cancer (of the bone marrow). Consult your doctor for more details. Tell your doctor immediately if you develop: swollen glands, unexplained or sudden weight loss, night sweats.

A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Temodar (Temozolomide)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Temodar FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Newly Diagnosed Glioblastoma Multiforme

During the concomitant phase (TEMODAR+radiotherapy), adverse reactions including thrombocytopenia, nausea, vomiting, anorexia, and constipation were more frequent in the TEMODAR+RT arm. The incidence of other adverse reactions was comparable in the two arms. The most common adverse reactions across the cumulative TEMODAR experience were alopecia, nausea, vomiting, anorexia, headache, and constipation (see Table 7). Forty-nine percent (49%) of patients treated with TEMODAR reported one or more severe or life-threatening reactions, most commonly fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia (5%). Overall, the pattern of reactions during the maintenance phase was consistent with the known safety profile of TEMODAR.

TABLE 7: Number (%) of Patients with Adverse Reactions: All and Severe/Life Threatening (Incidence of 5% or Greater)

  Concomitant Phase RT Alone
(n=285)
Concomitant Phase RT+TMZ
(n=288)*
Maintenance Phase TMZ
(n=224)
All Grade ≥ 3 All Grade ≥ 3 All Grade ≥ 3
Subjects Reporting any Adverse Reaction 258 (91) 74 (26) 266 (92) 80 (28) 206 (92) 82 (37)
Body as a Whole — General Disorders
Anorexia 25 (9) 1 ( < 1) 56 (19) 2 (1) 61 (27) 3 (1)
Dizziness 10 (4) 0 12 (4) 2 (1) 12 (5) 0
Fatigue 139 (49) 15 (5) 156 (54) 19 (7) 137 (61) 20 (9)
Headache 49 (17) 11 (4) 56 (19) 5 (2) 51 (23) 9 (4)
Weakness 9 (3) 3 (1) 10 (3) 5 (2) 16 (7) 4 (2)
Central and Peripheral Nervous System Disorders
Confusion 12 (4) 6 (2) 11 (4) 4 (1) 12 (5) 4 (2)
Convulsions 20 (7) 9 (3) 17 (6) 10 (3) 25 (11) 7 (3)
Memory Impairment 12 (4) 1 ( < 1) 8 (3) 1 ( < 1) 16 (7) 2 (1)
Disorders of the Eye
Vision Blurred 25 (9) 4 (1) 26 (9) 2 (1) 17 (8) 0
Disorders of the Immune System
Allergic Reaction 7 (2) 1 ( < 1) 13 (5) 0 6 (3) 0
Gastrointestinal System Disorders
Abdominal Pain 2 (1) 0 7 (2) 1 ( < 1) 11 (5) 1 ( < 1)
Constipation 18 (6) 0 53 (18) 3 (1) 49 (22) 0
Diarrhea 9 (3) 0 18 (6) 0 23 (10) 2 (1)
Nausea 45 (16) 1 ( < 1) 105 (36) 2 (1) 110 (49) 3 (1)
Stomatitis 14 (5) 1 ( < 1) 19 (7) 0 20 (9) 3 (1)
Vomiting 16 (6) 1 ( < 1) 57 (20) 1 ( < 1) 66 (29) 4 (2)
Injury and Poisoning
Radiation Injury NOS 11 (4) 1 ( < 1) 20 (7) 0 5 (2) 0
Musculoskeletal System Disorders
Arthralgia 2 (1) 0 7 (2) 1 ( < 1) 14 (6) 0
Platelet, Bleeding and Clotting Disorders
Thrombocytopenia 3 (1) 0 11 (4) 8 (3) 19 (8) 8 (4)
Psychiatric Disorders
Insomnia 9 (3) 1 ( < 1) 14 (5) 0 9 (4) 0
Respiratory System Disorders
Coughing 3 (1) 0 15 (5) 2 (1) 19 (8) 1 ( < 1)
Dyspnea 9 (3) 4 (1) 11 (4) 5 (2) 12 (5) 1 ( < 1)
Skin and Subcutaneous Tissue Disorders
Alopecia 179 (63) 0 199 (69) 0 124 (55) 0
Dry Skin 6 (2) 0 7 (2) 0 11 (5) 1 ( < 1)
Erythema 15 (5) 0 14 (5) 0 2 (1) 0
Pruritus 4 (1) 0 11 (4) 0 11 (5) 0
Rash 42 (15) 0 56 (19) 3 (1) 29 (13) 3 (1)
Special Senses Other, Disorders
Taste Perversion 6 (2) 0 18 (6) 0 11 (5) 0
*One patient who was randomized to RT only arm received RT+temozolomide. RT+TMZ=radiotherapy plus temozolomide; NOS=not otherwise specified.
Note: Grade 5 (fatal) adverse reactions are included in the Grade ≥ 3 column.

Myelosuppression (neutropenia and thrombocytopenia), which is a known dose-limiting toxicity for most cytotoxic agents, including TEMODAR, was observed. When laboratory abnormalities and adverse reactions were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic reactions were observed in 8% of the patients, and Grade 3 or Grade 4 platelet abnormalities, including thrombocytopenic reactions, were observed in 14% of the patients treated with TEMODAR.

Refractory Anaplastic Astrocytoma

Tables 8 and 9 show the incidence of adverse reactions in the 158 patients in the anaplastic astrocytoma study for whom data are available. In the absence of a control group, it is not clear in many cases whether these reactions should be attributed to temozolomide or the patients' underlying conditions, but nausea, vomiting, fatigue, and hematologic effects appear to be clearly drug-related. The most frequently occurring adverse reactions were nausea, vomiting, headache, and fatigue. The adverse reactions were usually NCI Common Toxicity Criteria (CTC) Grade 1 or 2 (mild to moderate in severity) and were self-limiting, with nausea and vomiting readily controlled with antiemetics. The incidence of severe nausea and vomiting (CTC Grade 3 or 4) was 10% and 6%, respectively. Myelosuppression (thrombocytopenia and neutropenia) was the dose-limiting adverse reaction. It usually occurred within the first few cycles of therapy and was not cumulative.

Myelosuppression occurred late in the treatment cycle and returned to normal, on average, within 14 days of nadir counts. The median nadirs occurred at 26 days for platelets (range: 21-40 days) and 28 days for neutrophils (range: 1-44 days). Only 14% (22/158) of patients had a neutrophil nadir and 20% (32/158) of patients had a platelet nadir, which may have delayed the start of the next cycle. Less than 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression.

In clinical trial experience with 110 to 111 women and 169 to 174 men (depending on measurements), there were higher rates of Grade 4 neutropenia (ANC less than 500 cells/μL) and thrombocytopenia (less than 20,000 cells/μL) in women than men in the first cycle of therapy (12% vs. 5% and 9% vs. 3%, respectively).

In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 9.5% (6/63) of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients less than or equal to age 70, 7% (62/871) and 5.5% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia have also been reported.

TABLE 8: Adverse Reactions in the Anaplastic Astrocytoma Trial in Adults ( ≥ 5%)

  No. (%) of TEMODAR Patients (N=158)
All Reactions Grade 3/4
Any Adverse Reaction 153(97) 79(50)
Body as a Whole
Headache 65(41) 10(6)
Fatigue 54(34) 7(4)
Asthenia 20(13) 9(6)
Fever 21(13) 3(2)
Back pain 12(8) 4(3)
Cardiovascular
Edema peripheral 17(11) 1(1)
Central and Peripheral Nervous System
Convulsions 36(23) 8(5)
Hemiparesis 29(18) 10(6)
Dizziness 19(12) 1(1)
Coordination abnormal 17(11) 2(1)
Amnesia 16(10) 6(4)
Insomnia 16(10) 0
Paresthesia 15(9) 1(1)
Somnolence 15(9) 5(3)
Paresis 13(8) 4(3)
Urinary incontinence 13(8) 3(2)
Ataxia 12(8) 3(2)
Dysphasia 11(7) 1(1)
Convulsions local 9(6) 0
Gait abnormal 9(6) 1(1)
Confusion 8(5) 0
Endocrine
Adrenal hypercorticism 13(8) 0
Gastrointestinal System
Nausea 84(53) 16(10)
Vomiting 66(42) 10(6)
Constipation 52(33) 1(1)
Diarrhea 25(16) 3(2)
Abdominal pain 14(9) 2(1)
Anorexia 14(9) 1(1)
Metabolic
Weight increase 8(5) 0
Musculoskeletal System
Myalgia 8(5)
Psychiatric Disorders
Anxiety 11(7) 1(1)
Depression 10(6) 0
Reproductive Disorders
Breast pain, female 4(6)
Resistance Mechanism Disorders
Infection viral 17(11) 0
Respiratory System
Upper respiratory tract infection 13(8) 0
Pharyngitis 12(8) 0
Sinusitis 10(6) 0
Coughing 8(5) 0
Skin and Appendages
Rash 13(8) 0
Pruritus 12(8) 2(1)
Urinary System
Urinary tract infection 12(8) 0
Micturition increased frequency 9(6) 0
Vision
Diplopia 8(5) 0
Vision abnormal* 8 (5)
*Blurred vision; visual deficit; vision changes; vision troubles

TABLE 9: Adverse Hematologic Effects (Grade 3 to 4) in the Anaplastic Astrocytoma Trial in Adults

  TEMODAR*
Hemoglobin 7/158 (4%)
Lymphopenia 83/152 (55%)
Neutrophils 20/142 (14%)
Platelets 29/156 (19%)
WBC 18/158 (11%)
*Change from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.

TEMODAR for injection delivers equivalent temozolomide dose and exposure to both temozolomide and 5-(3-methyltriazen-1yl)-imidazole-4-carboxamide (MTIC) as the corresponding TEMODAR capsules. Adverse reactions probably related to treatment that were reported from the 2 studies with the intravenous formulation (n=35) that were not reported in studies using the TEMODAR capsules were: pain, irritation, pruritus, warmth, swelling, and erythema at infusion site as well as the following adverse reactions: petechiae and hematoma.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of TEMODAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.

Dermatologic disorders: Toxic epidermal necrolysis and Stevens-Johnson syndrome

Immune system disorders: Allergic reactions, including anaphylaxis. Erythema multiforme, which resolved after discontinuation of TEMODAR and, in some cases, recurred upon rechallenge.

Hematopoietic disorders: Prolonged pancytopenia, which may result in aplastic anemia and fatal outcomes [see WARNINGS AND PRECAUTIONS].

Hepatobiliary disorders: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, and hepatitis [see WARNINGS AND PRECAUTIONS].

Infections and infestations: Opportunistic infections including Pneumocystis pneumonia (PCP) [see WARNINGS AND PRECAUTIONS].

Pulmonary disorders: Interstitial pneumonitis, pneumonitis, alveolitis, and pulmonary fibrosis.

Read the entire FDA prescribing information for Temodar (Temozolomide) »

A A A

Temodar - User Reviews

Temodar User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Temodar sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.